Article Details
Retrieved on: 2025-09-20 20:50:04
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
This acquisition, which includes the late-stage MASH drug pegozafermin, aims to expand Roche's portfolio in cardiovascular, renal, and metabolic ...
Article found on: www.ainvest.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here